Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Articles

Pages

120 items
7:37 PM, Sep 13, 2018  |  BC Innovations | Product R&D

Academia’s manufacturing problem

With backups at academic manufacturing centers beginning to hamper translation of early stage gene therapies, pushing those who can afford it to CMOs, at least one non-profit has stepped in with a model to deliver...
3:08 PM, Aug 23, 2018  |  BC Innovations | Product R&D

Sweet switch

Novo Nordisk A/S is betting Ziylo Ltd.’s glucose-responsive compounds can unlock development of smart insulins that are a step up for diabetes therapy. Unlike the competitors, which mostly act when blood glucose is high, Ziylo’s...
5:47 PM, Jul 26, 2018  |  BC Innovations | Product R&D

Syncona’s sister act

With the final pieces of its gene therapy portfolio in place, Syncona Investment Management Ltd. thinks its five “sister companies” are poised to capitalize on recent regulatory and technological advances in gene therapy, and push...
2:58 PM, Jul 17, 2018  |  BC Innovations | Product R&D

Natural spots

With a new take on allosteric modulation, HotSpot Therapeutics Inc. has emerged from stealth mode to find specialized niches on proteins that nature uses to control their activity. The company’s platform has identified druggable allosteric...
11:52 AM, Jul 12, 2018  |  BC Innovations | Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
5:43 PM, Jun 28, 2018  |  BC Innovations | Product R&D

Highly personal

Pact Pharma Inc. has raised $120 million in venture financing to tackle one of the most complex forms of personalized medicine proposed to date: neoantigen-targeted T cells. Backed by Alphabet Inc.’s GV, the company is...
4:59 PM, Jun 21, 2018  |  BC Innovations | Product R&D

Tusk’s take on CD25

As companies revisit the potential of IL-2 to aid cancer immunotherapy, Tusk Therapeutics Ltd. has a new take by attacking CD25, a component of the IL-2 receptor with its own storied past. Its antibody could...
12:02 PM, May 31, 2018  |  BC Innovations | Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
5:36 PM, May 24, 2018  |  BC Innovations | Product R&D

Peptides step up

New screening platforms and synthetic approaches could finally solve some of the longstanding hurdles to turning antimicrobial peptides into therapeutic candidates to combat antibacterial resistance, overcoming their history of limited clinical efficacy, systemic toxicity and...
4:17 PM, May 24, 2018  |  BC Innovations | Product R&D

Bias-less bispecifics

Taking a leaf from the small molecule playbook, cancer play Merus N.V. is bringing unbiased screening to the bispecifics space. The biotech is betting the approach can discover bispecific antibodies with novel activity against known...

Pages